share_log

Zenvia Analyst Ratings

Benzinga Analyst Ratings ·  Feb 13, 2023 22:28
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
02/13/2023 7.44% UBS $11 → $1.3 Downgrades Buy → Neutral
09/06/2022 139.67% Goldman Sachs $3.4 → $2.9 Maintains Neutral
07/08/2022 230.58% Morgan Stanley $12 → $4 Downgrades Overweight → Equal-Weight
07/05/2022 180.99% Goldman Sachs → $3.4 Downgrades Buy → Neutral
01/19/2022 1346.28% Goldman Sachs $30.5 → $17.5 Maintains Buy
08/23/2021 1949.59% Itau BBA → $24.8 Initiates Coverage On → Outperform
08/16/2021 2792.56% Goldman Sachs → $35 Initiates Coverage On → Buy

What is the target price for Zenvia (ZENV)?

The latest price target for Zenvia (NASDAQ: ZENV) was reported by UBS on February 13, 2023. The analyst firm set a price target for $1.30 expecting ZENV to rise to within 12 months (a possible 7.44% upside). 4 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Zenvia (ZENV)?

The latest analyst rating for Zenvia (NASDAQ: ZENV) was provided by UBS, and Zenvia downgraded their neutral rating.

When is the next analyst rating going to be posted or updated for Zenvia (ZENV)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Zenvia, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Zenvia was filed on February 13, 2023 so you should expect the next rating to be made available sometime around February 13, 2024.

Is the Analyst Rating Zenvia (ZENV) correct?

While ratings are subjective and will change, the latest Zenvia (ZENV) rating was a downgraded with a price target of $11.00 to $1.30. The current price Zenvia (ZENV) is trading at is $1.21, which is out of the analyst's predicted range.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment